tiprankstipranks
Shuttle Pharma Raises $4.5M for Clinical Trials
Company Announcements

Shuttle Pharma Raises $4.5M for Clinical Trials

Don't Miss Our Christmas Offers:

An announcement from Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) is now available.

Shuttle Pharmaceuticals Holdings, Inc. has successfully closed a public offering, raising approximately $4.5 million to support clinical trials, including $2.3 million earmarked for Phase II trials of their radiation sensitizer, Ropidoxuridine. This offering, priced at $1.525 per share with accompanying warrants, aims to bolster the company’s efforts in developing therapies to enhance radiation therapy outcomes for cancer patients. Leading placement agents A.G.P./Alliance Global Partners and Boustead Securities facilitated the offering, which is expected to advance Shuttle Pharma’s clinical development initiatives.

See more data about SHPH stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyShuttle Pharmaceuticals enters into sponsored research agreement with UCSF
TipRanks Auto-Generated NewsdeskShuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma
TheFlyShuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App